Ischemic Stroke Clinical Trial
Official title:
Efficacy of Virtual Reality Exercises Using Wii Gaming Technology in STroke Rehabilitation: A Multicentre Randomized Clinical Trial (EVREST Multicentre)
| Verified date | November 2015 |
| Source | St. Michael's Hospital, Toronto |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Canada: Ethics Review Committee |
| Study type | Interventional |
A multicentre, randomized, two parallel group study comparing virtual reality using Wii
gaming technology versus Recreational activities in patients receiving conventional
rehabilitation after an ischemic stroke.
Primary Hypothesis: Virtual reality using the Wii gaming system is more efficacious in
improving motor function than recreational therapy among patients receiving conventional
rehabilitation following a recent ischemic stroke.
| Status | Completed |
| Enrollment | 141 |
| Est. completion date | October 2015 |
| Est. primary completion date | October 2015 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 85 Years |
| Eligibility |
Inclusion Criteria: - Patient has provided written informed consent prior to entry into the study - Males or females, aged 18 to 85 years - In-patient at the time of randomization - Evidence of ischemic stroke confirmed by CT or MRI head scan - Patients with onset of symptoms less than 3 months at time of randomization - Measurable deficit of the upper extremity (arm) equal to or greater than 3 according to the Chedoke McMaster scale (e.g.: participants should be able to touch their chin and contralateral knee to be eligible) - Functional independence prior to present stroke (baseline mRS = 0-1) - Patient is alert, medically stable according to the treating physician and able to follow simple verbal commands Exclusion Criteria: - Acute stroke onset more than 3 months ago - Patient is unable to follow verbal commands or has global aphasia - Severe illness and life expectancy less than 3 months (cancer, endocarditis, metastasis with an occult primary malignancy, coagulopathy) - Uncontrolled hypertension according to the treating physician - Unstable angina or recent myocardial infarction (within the last 3 months), current NY Heart Association Class III (marked limitation of physical activity; although patients are comfortable at rest, less-than-ordinary activity leads to fatigue, dyspnea, palpitations, or angina) or IV (symptomatic at rest; symptoms of CHF are present at rest; discomfort increases with any physical activity) or symptomatic ventricular tachyarrhythmias, as per medical history (a baseline ECG will not be required.) - Any history of seizure, except for febrile seizures of childhood - Pain or joint problems limiting movement of the arm (e.g. shoulder pain) - Participation in another clinical trial involving rehabilitation (recreational therapy, occupational therapy, physiotherapy) or involving an investigational drug - Patient is unwilling or unable to comply with the protocol or cannot / will not cooperate fully with the investigator or study personnel - Any condition(s) that, in the Investigator's opinion, would a) warrant exclusion from the study (i.e., participation in the study is not in the best interest of the patient) or b) prevent the patient from completing the study. - Any medical condition that might confound the interpretation of results or put the patient at risk (amputation of one extremity). Enrollment Criteria - Upon meeting all eligibility criteria and providing written informed consent, the patient will be enrolled into the study contingent on successfully completing a one hour training session with Virtual Reality Wii. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)
| Country | Name | City | State |
|---|---|---|---|
| Argentina | FLENI | Buenos Aires | |
| Brazil | Lucy Montoro Network | Sao Paulo | |
| Canada | University of Calgary | Calgary | Alberta |
| Canada | Hamilton Health Sciences | Hamilton | Ontario |
| Canada | Parkwood Hospital, St. Joseph's Health Care London | London | Ontario |
| Canada | Trillium Health Partners | Mississauga | Ontario |
| Canada | CSSS Cavendish Richardson Hospital | Montreal | Quebec |
| Canada | Providence Healthcare | Scarborough | Ontario |
| Canada | LA Miller Centre | St John's | Newfoundland and Labrador |
| Canada | Toronto Rehabilitation Institute | Toronto | Ontario |
| Canada | Riverview Health Centre | Winnipeg | Manitoba |
| Peru | Clinica San Felipe | Lima | |
| Thailand | Siriraj Hospital | Bangkok |
| Lead Sponsor | Collaborator |
|---|---|
| St. Michael's Hospital, Toronto | Heart and Stroke Foundation of Ontario, Ontario Ministry of Health and Long Term Care, Ontario Stroke Network |
Argentina, Brazil, Canada, Peru, Thailand,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Difference in motor performance between groups measured using the Wolf Motor function Test. | Efficacy in motor function improvement at the end of the intervention will be measured by the abbreviated Wolf Motor Function Test. The Wolf MFT is a time-based method to evaluate upper extremity performance while providing insight into total limb movements. It consists of 15 timed measures and 2 force-based measures which progress in complexity. Difference in Wolf MFT is one of the most commonly used outcome measures in stroke rehabilitation trials. | 1 (±3) days after the end of the intervention | No |
| Secondary | Improvement in motor function, performing activities of daily living, and quality of life, as well as sustainability of motor improvement | Secondary efficacy outcome measures include Box & Block Test, quality of life as measured by the Stroke Impact Scale, and Barthel Index at the end of the interventions. In addition, sustainability of motor improvement will be assessed through the Wolf Motor Function Test and Box & Block Test conducted at 4 weeks post-intervention, which is approximately 3 months from stroke onset. | End of intervention and 4 weeks post-intervention | No |
| Secondary | Proportion of patients experiencing intervention-related adverse events or any serious adverse events during the study period | Secondary safety outcome will be measured as the proportion of patients experiencing intervention-related adverse events (e.g. pain, dizziness), or any serious adverse event (death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, or results in persistent or significant disability/incapacity) during the study period. We will also measure patients' perceived exertion after treatment by using the Borg Perceived Exertion scale (excessive fatigue defined as any score > 13 points) | Subjects will be followed for the duration of their participation in the study, an expected time frame of 6 weeks | Yes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
| Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
| Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
| Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
| Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
| Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
| Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
| Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
| Not yet recruiting |
NCT06462599 -
Osteopontin Gene Polymorphism in Stroke Patients in Egypt
|
||
| Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
| Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
| Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
| Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
| Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
| Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
| Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
| Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A | |
| Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 |